Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
trial tags : Therapy save search
Ocugen Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Modifier Gene Therapy
Published: 2024-04-19 (Crawled : 11:00) - globenewswire.com
OCGN | News A | $1.3 -1.52% 4.3M
|
Health Technology
|
| O: -15.41%
H: 0.0%
C: 0.0%
ocu410 armada trial therapy
Artiva Biotherapeutics Announces First Patient Dosed in Phase 1 Trial of AlloNK® Cell Therapy Candidate in Lupus Nephritis
Published: 2024-04-17 (Crawled : 15:00) - biospace.com/
AFMD | $5.05 -0.39% 56K
|
Health Technology
|
| O: -2.42%
H: 0.0%
C: 0.0%
allonk first candidate lupus cell trial therapy
Ocugen, Inc. Announces U.S. FDA Clearance of IND Amendment to Initiate OCU400 Phase 3 Clinical Trial — First Gene Therapy to Enter Phase 3 with a Broad Retinitis Pigmentosa Indication
Published: 2024-04-08 (Crawled : 11:00) - globenewswire.com
OCGN | News A | $1.3 -1.52% 4.3M
|
Health Technology
|
| O: 26.42%
H: 3.48%
C: -6.47%
ocu400 fda first clearance trial therapy
Phase 1/2 Interim Data on Moderna’s mRNA-3927, an Investigational mRNA Therapy for Propionic Acidemia, Published in Nature
Published: 2024-04-03 (Crawled : 19:00) - biospace.com/
MRNA S | $101.22 -0.77% 1.8M
|
Health Technology
|
| O: -0.59%
H: 2.09%
C: -1.74%
rna-3927 mrna therapy
Genprex Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa® Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer
Published: 2024-04-03 (Crawled : 12:30) - prnewswire.com
GNPX | $2.2194 35K
|
Health Technology
|
| O: 1.76%
H: 13.15%
C: 7.61%
reqorsa lung cancer treat cell trial therapy study
GenFleet and BeiGene Enter into Trial Collaboration for a Potentially First-in-class Combination Therapy to Initiate Phase Ib/II Study of GFH009 (CDK9 inhibitor) and BRUKINSA® (zanubrutinib) Treating Diffuse Large B Cell Lymphoma
Published: 2024-03-28 (Crawled : 11:00) - prnewswire.com
SLS | $1.54 1.32% 870K
|
Health Technology
|
| O: -0.97%
H: 1.18%
C: -0.98%
gfh009 brukinsa cell collaboration trial therapy study
FDA Rejects Regeneron’s Blood Cancer Therapy for Two Forms of Lymphoma
Published: 2024-03-25 (Crawled : 16:00) - biospace.com/
SNYNF | News | $92.7 600K
|
Health Technology
|
| O: -100.0%
H: NaN%
C: Infinity%
SNY | News | $46.545 2.55% 2.3M
|
Health Technology
|
| O: 0.42%
H: 0.0%
C: 0.0%
fda cancer blood therapy
RG6501 (OpRegen®) Phase 1/2a Clinical Study 24 Month Results to Be Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit
Published: 2024-03-13 (Crawled : 13:00) - biospace.com/
ERNA | $2.16 0.47% 3.5K
|
Information
|
| O: 4.1%
H: 0.0%
C: -11.81%
LCTX | $1.15 -4.17% 690K
|
Health Technology
|
| O: 1.61%
H: 2.38%
C: -3.97%
rg6501 opregen innovation cell therapy results study
City of Hope-developed Chimeric Antigen Receptor (CAR) T Cell Therapy Shows Clinical Activity in Patients With Aggressive Brain Tumors in a Phase 1 Trial
Published: 2024-03-07 (Crawled : 12:30) - biospace.com/
FNCTF | News | $11.0354 320
|
Communications
|
| O: 0.79%
H: 0.78%
C: 0.78%
MBIO | $0.356 -4.04% 130K
|
Health Technology
|
| O: 8.33%
H: 4.2%
C: -2.8%
FBIO | $1.75 -3.32% 150K
|
Health Technology
|
| O: 2.93%
H: 0.0%
C: -9.21%
tumors cell city trial therapy
BioCardia Reports Positive Interim Results from Phase III CardiAMP Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart Failure
Published: 2024-03-04 (Crawled : 13:00) - globenewswire.com
BCDA | $0.377 48K
|
Health Technology
|
| O: 0.03%
H: 1.72%
C: -21.53%
biomarker positive cell cardiamp heart therapy results
Global PRMT5 Targeted Therapy Market & Clinical Trials Opportunity Outlook 2024: PRMT5 Targeted Therapies Clinical Trials by Company, Indication & Phase
Published: 2024-02-28 (Crawled : 23:00) - prnewswire.com
JNJ | News | $147.895 1.48% 5.8M
|
Health Technology
|
| O: 0.56%
H: 0.12%
C: -0.38%
trials global therapy market
Gain Therapeutics Announces the Initiation of the Multiple Ascending Dose (MAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson’s Disease
Published: 2024-02-27 (Crawled : 19:00) - globenewswire.com
GANX | $3.1 -1.59% 44K
|
Professional, Scientific, and T...
|
| O: 0.22%
H: 3.45%
C: -3.88%
gt-0228 disease parkinson’s trial therapeutics therapy
Actinium Announces Iomab-B Markedly Increases Long Term Survival in Patients 65 Years or Older with Active Relapsed or Refractory AML in the Phase 3 SIERRA Trial at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR®
Published: 2024-02-26 (Crawled : 12:30) - prnewswire.com
ATNM | $6.72 0.75% 220K
|
Health Technology
|
| O: 2.04%
H: 19.98%
C: 18.71%
astct active aml trial therapy
Actinium Highlights Improved Survival with Iomab-B in TP53 Positive Relapsed Refractory Acute Myeloid Leukemia Patients in the SIERRA Trial and Other Presentations at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR®
Published: 2024-02-23 (Crawled : 12:30) - prnewswire.com
ATNM | $6.72 0.75% 220K
|
Health Technology
|
| O: 4.45%
H: 1.85%
C: -2.56%
tp53 astct positive leukemia trial therapy
First Refractory Gastric Cancer Patient Dosed in Phase 2 Trial with Novel Combination of MiNK’s Allogeneic INKT Cell Therapy and Agenus’ Botensilimab and Balstilimab
Published: 2024-02-14 (Crawled : 13:00) - globenewswire.com
INKT | $0.898 3.02% 38K
|
|
| O: 1.33%
H: 6.34%
C: 6.34%
first cancer cell trial therapy
Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Disease-Free Survival (DFS) as Adjuvant Therapy Versus Observation in High-Risk Patients With Localized Muscle-Invasive and Locally Advanced Urothelial Carcinoma After Surgery
Published: 2024-01-26 (Crawled : 23:00) - biospace.com/
MRK | $125.8 0.46% 3.4M
|
Health Technology
|
| O: 0.32%
H: 0.42%
C: 0.26%
keytruda advanced therapy
Positive Phase 1/2 Clinical Trial Data for an Investigational Gene Therapy for Genetic Hearing Loss to be Presented at the Association for Research in Otolaryngology 2024 MidWinter Meeting
Published: 2024-01-23 (Crawled : 17:00) - prnewswire.com
LLY | $727.48 -2.48% 2M
|
Health Technology
|
| O: -0.51%
H: 0.37%
C: 0.32%
genetic association positive research meeting trial therapy
Panbela Announces Publication of Clinical Data Titled: Phase 1 study of high-dose DFMO, celecoxib, cyclophosphamide and topotecan for patients with relapsed neuroblastoma: A New Approaches to Neuroblastoma Therapy Trial
Published: 2024-01-18 (Crawled : 13:00) - globenewswire.com
PBLA | $0.4895 66K
|
Professional, Scientific, and T...
|
| O: -5.49%
H: 0.0%
C: -18.9%
publication trial therapy study
First Patient Dosed in Trial Evaluating Efti and the Anti-PD-L1 Therapy BAVENCIO® in Metastatic Urothelial Cancer
Published: 2024-01-04 (Crawled : 13:00) - globenewswire.com
IMMP | News | $2.23 1.36% 57K
|
Health Technology
|
| O: -0.43%
H: 5.22%
C: 4.78%
bavencio first cancer trial therapy
Innovent and Xuanzhu Enter into Clinical Trial Collaboration Investigating Combination Therapy of Sintilimab (PD-1 inhibitor) and A Novel ADC Candidate for Advanced Solid Tumors in China
Published: 2023-12-28 (Crawled : 00:00) - prnewswire.com
SNYNF | News | $92.7 600K
|
Health Technology
|
| O: 0.28%
H: 0.0%
C: -1.32%
LLY | $727.48 -2.48% 2M
|
Health Technology
|
| O: 0.08%
H: 0.81%
C: -0.19%
SNY | News | $46.545 2.55% 2.3M
|
Health Technology
|
| O: 0.52%
H: 0.72%
C: -0.34%
INCY | $52.07 -1.42% 800K
|
Health Technology
|
| O: 0.35%
H: 1.07%
C: -0.27%
candidate tumors collaboration trial advanced china therapy
Gainers vs Losers
| 70% | 30% |
Top 10 Gainers
AGBA | News | $1.305 226.25% 130M
|
Finance
EGOX | $0.0503 39.72% 320M
|
RWOD | $10.52 31.56% 5.9M
|
n/a
ZCMD | $1.905 31.38% 30M
|
Commercial Services
MRDB 4 | $0.536 27.65% 2M
|
n/a
BSFC | $0.0822 27.64% 75M
|
Manufacturing
TPET | $0.4121 25.68% 45M
|
n/a
NVFY | $2.65 25.59% 33M
|
Consumer Durables
INDO | $5.1 25.0% 15M
|
Energy Minerals
CHRO | $1.53 24.9% 100K
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.